0 Items
Select Page

Bordetella pertussis

Bordetella Pertussis is the causative agent of whooping cough, a highly contagious respiratory disease, known for uncontrollable, violent coughing which often makes it hard to breathe.

Our Bordetella pertussis product range includes several formats of pertussis toxin and also purified FHA antigen. In addition to applications for vaccine research and within diagnostics kits, our toxin is highly active and widely used in cell biology studies of GTP binding proteins.

Bordetella pertussis Background

Bordetella Pertussis is a gram-negative coccobacillus that belongs to the genus Bordetella. First described in 1906, B. pertussis infection causes a highly contagious respiratory disease in humans, known as whooping cough or pertussis. The organism is thought to be transmitted between humans by aerosol droplets but does not survive for long periods in the environment.

Pertussis infection is localised to the respiratory tract and usually gives causes general malaise followed by a paroxysmal period of coughing lasting 1-6 weeks. Reports suggest that infection may cause an increase in lymphocyte numbers, causing confusion and other neurological symptoms. These symptoms may be caused by B. pertussis virulence factors (Hewlett, EL), which include pertussis toxin, filamentous haemagglutinin, pertactin, adenylate cyclase toxin and tracheal cytotoxin. Currently, the precise mechanism of pathogenesis is still unknown and the relevance of these and other potential virulence factors is still to be determined (CDC).

Until the introduction of a successful vaccine in the 1940s, whooping cough was a common illness in young children worldwide and a major cause of childhood mortality. Subsequent widespread vaccination resulted in a significant decrease in the number of cases worldwide. However, in recent years the number of reported cases have been rising in the developed world. Cases of infection have also been reported in adolescents, young adults and infants that are too young to vaccinate. These reports raise concerns regarding the efficacy of the vaccine currently in use and the possibility of waning immunity in vaccinated individuals (Hartzell, JD).

Currently, diagnosis of infection is achieved using serological techniques and molecular subtyping. However, correct diagnosis is complicated by the fact that symptoms of B. pertussis resemble other respiratory diseases in the early stages, driving a need for more sensitive methods of detection and diagnosis.

References

  1. Hewlett, EL (2014). Pertussis Pathogenesis—What We Know and What We Don’t Know. J Infect Dis.209(7): 982–985.
  2. Centers for Disease Control and Prevention: Pertussis (whooping cough)
  3. Hartzell, JD and Blaylock, JM (2014). Whooping cough in 2014 and beyond: an update and review. Chest.146(1):205-214.

Bordetella pertussis Antigens

The Native Antigen Company offers two key Bordetella pertussis antigens: the pertussis toxin, and filamentous haemagglutinin (FHA).

Pertussis toxin is most commonly used in immunoassay manufacture and cell biologists studying GTP receptor biology. To meet the variety of needs, we offer pertussis toxin in a range of different formats.

FHA is increasingly used in immunoassays, monitoring responses to pertussis vaccination.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

What should you call your favourite virus?

The International Committee on Taxonomy of Viruses (ICTV) meet regularly to ensure the taxonomy of viruses is kept logical and up-to-date in the face of an ever-increasing number of new viruses and genome sequences; discussed in here in Nature. This sometimes results...

Overcoming Zika-Dengue cross-reactivity: the highly specific immunoassays your lab needs

In the global battle against Zika virus, serological cross-reactivity with Dengue is a major challenge for academics, epidemiologists and pharmaceutical companies alike. Novel immunoassays can now overcome this problem and could prove a real game-changer in Zika...

The Right Tools for Rubella

Rubella remains a significant pathogen worldwide, with 100,000 cases of congenital rubella syndrome estimated to occur every year. Vaccines to Rubella are highly safe and have effectively eliminated endemic infection in many developed countries, yet inadequate...

Visualising viral infection with immunofluorescence microscopy

Following the latest immunofluoresence data for our Zika and Dengue antibodies, we’ve invited VRS to write a short blog one of their areas of expertise: The applications of immunofluorescence microscopy in studying viruses.   A lot of what we know about biology...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 9 =

Live Customer Feedback